Urologists 'Outraged' Over PSA Test Challenge
The nation's leading urology associations are fuming over a federal panel's report this week that discredits the widely used prostate-specific antigen screening test for prostate cancer.
The U.S. Preventive Services Task Force said in a report that the PSA test is too inaccurate, creates needless anxiety for patients, and can lead to costly and potentially harmful follow-up procedures.
"The USPSTF concludes that there is moderate certainty that the benefits of PSA-based screening for prostate cancer do not outweigh the harm," the report stated.
Major urology associations knew in advance about the USPSTF recommendation and urologists launched a counterattack when the report was made public this week.
"It's an absurd recommendation. It is ill-researched and ill-conceived," Sanford J. Siegel, MD, a board member with the Large Urology Group Practice Association, told HealthLeaders Media. "This will only do damage to all the great work that has been done for prostate cancer awareness and to control the deaths from prostate cancer."
- WellPoint Dominates Nearly Half of Markets, AMA Says
- CMS Offers Some ACOs $114M for 'Upfront' Costs
- Ebola: Second TX Nurse Diagnosed After Improper Protective Gear Application
- 16 Medicare Advantage Plans Earn 5-Star Ratings
- Providers Ask HHS to Address EHR Interoperability Barriers
- How Top-Ranked MA Plans Earn Their Stars
- Ebola: A Call for Designated Hospitals
- What Physician Alignment Means Depends on Who You Ask
- The Drug Price Reform Debate
- CMS' new investment model will help ACOs with health IT